Catalent, Inc. (NYSE:CTLT) Receives $59.83 Average Target Price from Analysts

Catalent, Inc. (NYSE:CTLT - Get Free Report) has received an average rating of "Hold" from the eight brokerages that are covering the stock, MarketBeat Ratings reports. Eight analysts have rated the stock with a hold rating. The average 12 month target price among brokers that have covered the stock in the last year is $59.83.

Several analysts have issued reports on the company. Barclays boosted their price objective on Catalent from $47.00 to $63.00 and gave the stock an "equal weight" rating in a report on Friday, June 28th. Baird R W cut Catalent from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, September 24th. William Blair reissued a "market perform" rating on shares of Catalent in a research note on Tuesday, September 3rd. StockNews.com began coverage on Catalent in a research note on Saturday. They issued a "hold" rating for the company. Finally, Robert W. Baird reissued a "neutral" rating and issued a $63.50 price target on shares of Catalent in a research note on Tuesday, September 24th.

Catalent Stock Performance

Shares of NYSE CTLT traded down $0.26 during trading on Friday, reaching $60.45. The stock had a trading volume of 1,425,004 shares, compared to its average volume of 2,060,076. The stock has a market cap of $10.94 billion, a PE ratio of -9.91, a P/E/G ratio of 2.14 and a beta of 1.15. The firm's 50 day moving average price is $60.03 and its two-hundred day moving average price is $57.65. The company has a debt-to-equity ratio of 1.35, a quick ratio of 1.96 and a current ratio of 2.52. Catalent has a one year low of $31.80 and a one year high of $61.20.

Catalent (NYSE:CTLT - Get Free Report) last issued its quarterly earnings data on Thursday, August 29th. The company reported $0.57 EPS for the quarter, topping analysts' consensus estimates of $0.44 by $0.13. Catalent had a negative return on equity of 0.56% and a negative net margin of 22.72%. The firm had revenue of $1.30 billion during the quarter, compared to the consensus estimate of $1.23 billion. On average, research analysts forecast that Catalent will post 0.95 earnings per share for the current fiscal year.

Insider Activity at Catalent

In related news, CEO Alessandro Maselli sold 9,088 shares of the company's stock in a transaction on Monday, July 29th. The stock was sold at an average price of $58.76, for a total value of $534,010.88. Following the completion of the transaction, the chief executive officer now directly owns 177,521 shares in the company, valued at approximately $10,431,133.96. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, CEO Alessandro Maselli sold 9,088 shares of the company's stock in a transaction on Monday, July 29th. The stock was sold at an average price of $58.76, for a total value of $534,010.88. Following the completion of the transaction, the chief executive officer now directly owns 177,521 shares in the company, valued at approximately $10,431,133.96. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider David Mcerlane sold 1,994 shares of the company's stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $59.97, for a total value of $119,580.18. Following the completion of the transaction, the insider now owns 36,304 shares of the company's stock, valued at $2,177,150.88. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 12,410 shares of company stock worth $732,680. 0.31% of the stock is owned by corporate insiders.

Institutional Trading of Catalent

Large investors have recently bought and sold shares of the stock. Thurston Springer Miller Herd & Titak Inc. bought a new stake in shares of Catalent during the second quarter worth $42,000. Mather Group LLC. bought a new stake in shares of Catalent during the first quarter worth $52,000. Longfellow Investment Management Co. LLC grew its holdings in shares of Catalent by 45.7% during the second quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company's stock worth $55,000 after purchasing an additional 305 shares during the last quarter. GAMMA Investing LLC grew its holdings in shares of Catalent by 25.9% during the second quarter. GAMMA Investing LLC now owns 1,032 shares of the company's stock worth $58,000 after purchasing an additional 212 shares during the last quarter. Finally, Sound Income Strategies LLC grew its holdings in shares of Catalent by 4,466.7% during the first quarter. Sound Income Strategies LLC now owns 1,370 shares of the company's stock worth $77,000 after purchasing an additional 1,340 shares during the last quarter.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.